LMDX LUMIRADX LTD

LumiraDx Announces its Securities will be Suspended from Trading on Nasdaq at the Open of Business on January 9th

LumiraDx Announces its Securities will be Suspended from Trading on Nasdaq at the Open of Business on January 9th

LONDON, Jan. 05, 2024 (GLOBE NEWSWIRE) -- LumiraDx Limited (Nasdaq: LMDX)(the “Company”) today announced that it has received notification from The Nasdaq Stock Market LLC (“Nasdaq”) that its securities will be suspended from trading at the open of business on January 9, 2024 as a result of the Company’s failure to maintain compliance with Nasdaq’s continued listing standards.

As previously disclosed, on October 24, 2023, the Company received a notice from Nasdaq’s Listing Qualifications Department (the “Staff”) stating that the Company’s securities were subject to delisting from The Nasdaq Global Market due to a failure to maintain compliance with the minimum bid price requirement of Nasdaq’s continued listing standards. The Company appealed the Staff’s determination and a hearing was scheduled for January 18, 2024.

On December 29, 2023, the Company announced the appointment of joint administrators for two of its subsidiaries, LumiraDx Group Limited and LumiraDx International Limited, which together hold substantially all of the assets of the LumiraDx group. The administrators have signed a definitive agreement to sell certain companies of the LumiraDx group related to LumiraDx’s innovative point of care technology to Roche. In light of these events, on December 29, 2023, the Company’s Board of Directors approved the withdrawal of the Company’s appeal in anticipation of the delisting of the Company’s securities from Nasdaq.

On January 5, 2024, the Company received a letter from Nasdaq confirming the Company’s withdrawal of its appeal and stating that Nasdaq intends to suspend the Company’s securities from trading at the open of business on January 9, 2024 and will file a Form 25 with the U.S. Securities and Exchange Commission when all internal procedural periods have run.

About LumiraDx

LumiraDx Limited (Nasdaq: LMDX) is a next-generation point of care diagnostics company that is transforming community-based healthcare. Its actively controlled microfluidic technology provides fast, high performance and accessible diagnostic solutions wherever the patient is for nearly any testing scenario, creating unique testing options at the point of need.

The Company offers a broad menu of lab comparable tests on a single portable Platform, with more than 30 assays on the market and in the pipeline, covering infectious diseases, cardiovascular diseases, diabetes, and coagulation disorders. The Company also supports high-complexity laboratory testing in an accessible high-throughput format to leverage current molecular laboratory operations.

Founded in 2014 and based in the UK, LumiraDx's diagnostic testing solutions are being deployed globally by governments and leading healthcare institutions across laboratories, urgent care, physician offices, pharmacies, schools, and workplaces to help screen, diagnose, and monitor wellness as well as disease. More information on LumiraDx is available at .

 



Contact:  
EN
05/01/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on LUMIRADX LTD

 PRESS RELEASE

LumiraDx Announces its Securities will be Suspended from Trading on Na...

LumiraDx Announces its Securities will be Suspended from Trading on Nasdaq at the Open of Business on January 9th LONDON, Jan. 05, 2024 (GLOBE NEWSWIRE) -- LumiraDx Limited (Nasdaq: LMDX)(the “Company”) today announced that it has received notification from The Nasdaq Stock Market LLC (“Nasdaq”) that its securities will be suspended from trading at the open of business on January 9, 2024 as a result of the Company’s failure to maintain compliance with Nasdaq’s continued listing standards. As previously disclosed, on October 24, 2023, the Company received a notice from Nasdaq’s Listing Qu...

 PRESS RELEASE

LumiraDx Announces Agreement to Sell its Cutting Edge Point of Care Te...

LumiraDx Announces Agreement to Sell its Cutting Edge Point of Care Technology Platform to Roche LONDON, Dec. 29, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited (Nasdaq: LMDX) (the “Company”), a next generation point of care diagnostics company, announced today the appointment of joint administrators for two of its subsidiaries. The administrators have signed a definitive agreement to sell certain companies of the LumiraDx group related to LumiraDx’s innovative point of care technology to Roche. The Company announced today that Andrew Johnson, Lisa Rickelton and Lindsay Hallam of FTI Consulti...

 PRESS RELEASE

LumiraDx Announces Receipt of NASDAQ Delisting Determination; Plans to...

LumiraDx Announces Receipt of NASDAQ Delisting Determination; Plans to Appeal LONDON, Oct. 27, 2023 (GLOBE NEWSWIRE) -- On October 24, 2023, LumiraDx Limited (Nasdaq: LMDX)(the “Company”) received a notice (“Notice”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) stating that on April 21, 2023, the Staff had notified the Company that the bid price of its listed securities had closed at less than $US1.00 per share over the previous 30 consecutive business days, and, as a result, did not comply with Listing Rule 5450(a)(1) (the “Minimum Bi...

 PRESS RELEASE

LumiraDx Partners with AstraZeneca & Everton in the Community to Set U...

LumiraDx Partners with AstraZeneca & Everton in the Community to Set Up England’s First Heart & Lung Screening Hub Made possible thanks to unrestricted grant funding from AstraZeneca and run by the official charity of Everton Football Club – Everton in the Community – the Liverpool-based hub will provide significant support for individuals suffering from chronic breathlessness and other heart and lung-related conditions in a community-based setting.The LumiraDx NT-proBNP test is the only NT-proBNP test currently available that can be used with a simple fingerstick sample.Run on the LumiraDx...

 PRESS RELEASE

LumiraDx to Announce Second Quarter Financial Results and Host Quarter...

LumiraDx to Announce Second Quarter Financial Results and Host Quarterly Conference Call on August 24 LONDON, Aug. 16, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited  (Nasdaq: LMDX), a next-generation point of care (POC) diagnostics company, announced it will release its second quarter financial results on Thursday, August 24, 2023. On the day of the release, LumiraDx will host a conference call and webcast at 8:30 AM Eastern Time to review the financial results and business highlights.    LumiraDx Second Quarter 2023 Financial Results Conference Call  Date:Thursday, August 24, 2023Time:8:30 A...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch